Why it is worth it for your practice.

MARKABLE is the objective mapping layer under your midlife care. You treat. We map and track. Here is what that does for the practice.

It saves clinician time, the expensive kind.

The 7-minute mapping is done before the visit, so the appointment opens straight on the care plan instead of history-taking. Across a full schedule, those saved minutes become real clinician capacity, the most expensive resource you have.

It sharpens the patient-clinician conversation.

She arrives with an objective profile and her top symptoms already flagged. Your clinician sees where to focus, and the trend since last visit gives every follow-up a shared, concrete reference point instead of starting from memory.

It keeps a long-term, high-value patient.

Midlife care is a multi-year relationship, not a one-time episode. When she can see her plan working between visits, she stays engaged in her care, and she stays with your practice.

A multi-year relationship

Midlife care is measured in years, not months.

A perimenopause patient is not a short episode. She is one of the longest care relationships in women's health.

Pregnancy care a defined episode

~9 mo

Perimenopause + menopause care ongoing

5 to 10+ years

02 yrs4 yrs6 yrs8 yrs10+ yrs

7+ yrs

Median time women live with menopausal symptoms, and often a decade or more.

~6 yrs

Typical time on hormone therapy, with no maximum duration per current guidance.

For life

Postmenopause continues indefinitely, so the care relationship can too.

Each retained patient is years of periodic visits and ongoing care. Retention is the return, and MARKABLE is built to help her stay in the care she needs.

Book a walkthrough See the clinician view Walk the patient journey

General wellness product for awareness and self-tracking. Not a medical device, not a reimbursable service, and not remote patient monitoring. It supports, but does not substitute for, clinical judgment. Duration figures describe perimenopause and menopause care in general and are not a claim about MARKABLE outcomes.

Sources: SWAN Study (Avis et al., JAMA Internal Medicine, 2015); The American College of Obstetricians and Gynecologists; The Menopause Society. Patent Pending. MARKABLE Ltd.